Eli Lilly & Co. rose to a one-month high after an analyst said success of the company’s experimental Alzheimer’s drug could double the share price.
Novo Nordisk A/S had the biggest drop in almost four years, losing about $14.2 billion of market value, after U.S. regulators rejected its new insulin.
Exchange-traded funds that own junk bonds are attracting unprecedented sums of cash from institutional investors seeking to slip in and out of the market as dealer inventories decline.
"The ups have generally exceeded the downs."
- Tim Anderson on Oct 29, 2014